| MUC4 altered in cohorts of …ALTERED_INderived28 of 28show fewer |
|---|
| → altered in cohorts of | Uterine Carcinosarcoma 45 / 57 cases (79 %) · ssm · TCGA-UCS | — | — | Uterine Carcinosarcoma | 1 | Observed | gdc | graph → |
| → altered in cohorts of | Cervical Carcinoma 224 / 306 cases (73 %) · ssm · TCGA-CESC · largest of 2 cohorts | — | — | Cervical Carcinoma | 2 | Observed | gdc | graph → |
| → altered in cohorts of | Head and Neck Squamous Cell Carcinoma 372 / 528 cases (70 %) · ssm · TCGA-HNSC · largest of 2 cohorts | — | — | Head and Neck Squamous Cell Carcinoma | 2 | Observed | gdc | graph → |
| → altered in cohorts of | Chromophobe Renal Cell Carcinoma 46 / 66 cases (70 %) · ssm · kich_tcga | — | — | Chromophobe Renal Cell Carcinoma | 1 | Observed | cbioportal | graph → |
| → altered in cohorts of | Skin Squamous Cell Carcinoma 27 / 39 cases (69 %) · ssm · cscc_hgsc_bcm_2014 | — | — | Skin Squamous Cell Carcinoma | 1 | Observed | cbioportal | graph → |
| → altered in cohorts of | Esophageal Carcinoma 128 / 185 cases (69 %) · ssm · TCGA-ESCA | — | — | Esophageal Carcinoma | 1 | Observed | gdc | graph → |
| → altered in cohorts of | Melanoma 37 / 144 cases (26 %) · ssm · mel_dfci_2019 · largest of 2 cohorts | — | — | Melanoma | 2 | Observed | cbioportal | graph → |
| → altered in cohorts of | Adrenal Cortical Carcinoma 21 / 90 cases (23 %) · ssm · acc_tcga | — | — | Adrenal Cortical Carcinoma | 1 | Observed | cbioportal | graph → |
| → altered in cohorts of | Colon Adenocarcinoma 20 / 106 cases (19 %) · ssm · coad_cptac_2019 | — | — | Colon Adenocarcinoma | 1 | Observed | cbioportal | graph → |
| → altered in cohorts of | Endometrial Carcinoma 90 / 517 cases (17 %) · ssm · ucec_tcga_pan_can_atlas_2018 · largest of 3 cohorts | — | — | Endometrial Carcinoma | 3 | Observed | cbioportal | graph → |
| → altered in cohorts of | Cervical Squamous Cell Carcinoma 50 / 291 cases (17 %) · ssm · cesc_tcga_pan_can_atlas_2018 · largest of 2 cohorts | — | — | Cervical Squamous Cell Carcinoma | 2 | Observed | cbioportal | graph → |
| → altered in cohorts of | Clear Cell Renal Cell Carcinoma 77 / 451 cases (17 %) · ssm · kirc_tcga · largest of 2 cohorts | — | — | Clear Cell Renal Cell Carcinoma | 2 | Observed | cbioportal | graph → |
| → altered in cohorts of | Esophageal Adenocarcinoma 29 / 185 cases (16 %) · ssm · esca_tcga | — | — | Esophageal Adenocarcinoma | 1 | Observed | cbioportal | graph → |
| → altered in cohorts of | Non-Seminomatous Germ Cell Tumor 24 / 155 cases (15 %) · ssm · tgct_tcga | — | — | Non-Seminomatous Germ Cell Tumor | 1 | Observed | cbioportal | graph → |
| → altered in cohorts of | Cutaneous Melanoma 55 / 368 cases (15 %) · ssm · skcm_tcga · largest of 3 cohorts | — | — | Cutaneous Melanoma | 3 | Observed | cbioportal | graph → |
| → altered in cohorts of | Endometrial Endometrioid Adenocarcinoma 32 / 247 cases (13 %) · ssm · uec_cptac_gdc | — | — | Endometrial Endometrioid Adenocarcinoma | 1 | Observed | cbioportal | graph → |
| → altered in cohorts of | Gastroesophageal Junction Adenocarcinoma 67 / 518 cases (13 %) · ssm · stes_tcga_pub | — | — | Gastroesophageal Junction Adenocarcinoma | 1 | Observed | cbioportal | graph → |
| → altered in cohorts of | Lung Squamous Cell Carcinoma 21 / 178 cases (12 %) · ssm · lusc_tcga_pub | — | — | Lung Squamous Cell Carcinoma | 1 | Observed | cbioportal | graph → |
| → altered in cohorts of | Gastric Adenocarcinoma 46 / 478 cases (9.6 %) · ssm · stad_tcga | — | — | Gastric Adenocarcinoma | 1 | Observed | cbioportal | graph → |
| → altered in cohorts of | B-Cell Non-Hodgkin Lymphoma 26 / 297 cases (8.8 %) · ssm · mbn_sfu_2023 | — | — | B-Cell Non-Hodgkin Lymphoma | 1 | Observed | cbioportal | graph → |
| → altered in cohorts of | Lung Adenocarcinoma 23 / 302 cases (7.6 %) · ssm · luad_oncosg_2020 | — | — | Lung Adenocarcinoma | 1 | Observed | cbioportal | graph → |
| → altered in cohorts of | Myelodysplastic Syndrome 69 / 1,026 cases (6.7 %) · ssm · mds_mskcc_2020 | — | — | Myelodysplastic Syndrome | 1 | Observed | cbioportal | graph → |
| → altered in cohorts of | Hepatocellular Carcinoma 25 / 373 cases (6.7 %) · ssm · lihc_tcga | — | — | Hepatocellular Carcinoma | 1 | Observed | cbioportal | graph → |
| → altered in cohorts of | Prostate Adenocarcinoma 26 / 444 cases (5.9 %) · ssm · prad_su2c_2019 · largest of 2 cohorts | — | — | Prostate Adenocarcinoma | 2 | Observed | cbioportal | graph → |
| → altered in cohorts of | Colorectal Adenocarcinoma 59 / 1,015 cases (5.8 %) · ssm · crc_sysucc_2022 · largest of 2 cohorts | — | — | Colorectal Adenocarcinoma | 2 | Observed | cbioportal | graph → |
| → altered in cohorts of | Diffuse Glioma 25 / 444 cases (5.6 %) · ssm · difg_glass_2019 · largest of 2 cohorts | — | — | Diffuse Glioma | 2 | Observed | cbioportal | graph → |
| → altered in cohorts of | Invasive Breast Carcinoma 53 / 982 cases (5.4 %) · ssm · brca_tcga · largest of 2 cohorts | — | — | Invasive Breast Carcinoma | 2 | Observed | cbioportal | graph → |
| → altered in cohorts of | Bladder Urothelial Carcinoma 24 / 474 cases (5.1 %) · ssm · blca_msk_tcga_2020 | — | — | Bladder Urothelial Carcinoma | 1 | Observed | cbioportal | graph → |